Colorectal drug candidates focal point of new collaboration between Servier, Celsius Therapeutics

A well-known international pharmaceutical company and a relatively new US precision therapeutics startup are joining forces to identify and validate novel colorectal cancer drug targets.

French pharma Servier and Cambridge, MA-based startup Celsius Therapeutics will work together over a three-year period to research, develop, and commercialize up to three of the most promising colorectal cancer drug discovery targets.